Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2017.1261824
Abstract: ABSTRACT Background: A previous meta-analysis demonstrated that 3 of the new-generation BCR-ABL tyrosine kinase inhibitors (TKIs) (dasatinib, nilotinib and ponatinib) are associated with an increased risk of vascular occlusive events in patients with Ph+ chronic… read more here.
Keywords: new generation; generation bcr; occlusive events; bcr abl ... See more keywords